OVID THERAPEUTICS DL-,001OVID THERAPEUTICS DL-,001OVID THERAPEUTICS DL-,001

OVID THERAPEUTICS DL-,001

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪203.27 M‬EUR
−0.66EUR
‪−47.42 M‬EUR
‪354.88 K‬EUR
‪57.53 M‬
Beta (1Y)
0.59

About Ovid Therapeutics Inc.

CEO
Jeremy Max Levin
Headquarters
New York
Website
Employees (FY)
40
Founded
2014
FIGI
BBG00GNRNS02
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange OVID THERAPEUTICS DL-,001 stocks are traded under the ticker 1OT.
We've gathered analysts' opinions on OVID THERAPEUTICS DL-,001 future price: according to them, 1OT price has a max estimate of 10.21 EUR and a min estimate of 3.25 EUR. Watch 1OT chart and read a more detailed OVID THERAPEUTICS DL-,001 stock forecast: see what analysts think of OVID THERAPEUTICS DL-,001 and suggest that you do with its stocks.
1OT reached its all-time high on May 19, 2017 with the price of 13.24 EUR, and its all-time low was 1.38 EUR and was reached on Jun 6, 2019. View more price dynamics on 1OT chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track OVID THERAPEUTICS DL-,001 financials in yearly and quarterly reports right on TradingView.
OVID THERAPEUTICS DL-,001 is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
1OT earnings for the last quarter are −0.16 EUR per share, whereas the estimation was −0.21 EUR resulting in a 23.93% surprise. The estimated earnings for the next quarter are −0.21 EUR per share. See more details about OVID THERAPEUTICS DL-,001 earnings.
OVID THERAPEUTICS DL-,001 revenue for the last quarter amounts to ‪137.16 K‬ EUR despite the estimated figure of ‪48.26 K‬ EUR. In the next quarter revenue is expected to reach ‪63.28 K‬ EUR.
1OT net income for the last quarter is ‪−10.84 M‬ EUR, while the quarter before that showed ‪−13.88 M‬ EUR of net income which accounts for 21.93% change. Track more OVID THERAPEUTICS DL-,001 financial stats to get the full picture.
No, 1OT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 23, 2024, the company has 40.00 employees. See our rating of the largest employees — is OVID THERAPEUTICS DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OVID THERAPEUTICS DL-,001 EBITDA is ‪−56.04 M‬ EUR, and current EBITDA margin is ‪−14.73 K‬%. See more stats in OVID THERAPEUTICS DL-,001 financial statements.
Like other stocks, 1OT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OVID THERAPEUTICS DL-,001 stock right from TradingView charts — choose your broker and connect to your account.